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Abstract
Background: Pelvic organ prolapse (POP) affects up to 40% of parous women which adversely affects the quality
of life. During a life time, 20% of all women will undergo an operation. In general the guidelines advise a vaginal
operation in case of uterine descent: hysterectomy with uterosacral ligament plication (VH), sacrospinous hysteropexy
(SSH) or a modified Manchester operation (MM). In the last decade, renewed interest in uterus sparing techniques has
been observed. Previous studies have shown non-inferiority between SSH and VH. Whether or not SSH and MM are
comparable concerning anatomical and functional outcome is still unknown. The practical application of both
operations is at least in The Netherlands a known cause of practice pattern variation (PPV). To reveal any difference
between both techniques the SAM-study was designed.
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Methods: The SAM-study is a randomized controlled multicentre non-inferiority study which compares SSH and MM.
Women with symptomatic POP in any stage, uterine descent and POP-Quantification (POP-Q) point D at ≤ minus 1 cm
are eligible. The primary outcome is the composite outcome at two years of absence of prolapse beyond the hymen
in any compartment, the absence of bulge symptoms and absence of reoperation for pelvic organ prolapse. Secondary
outcomes are hospital parameters, surgery related morbidity/complications, pain perception, further treatments for
prolapse or urinary incontinence, POP-Q anatomy in all compartments, quality-of-life, sexual function, and cost-
effectiveness. Follow-up takes place at 6 weeks, 12 and 24months. Additionally at 12 weeks, 6 and 9months cost-
effectiveness will be assessed. Validated questionnaires will be used and gynaecological examination will be performed.
Analysis will be performed following the intention-to-treat and per protocol principle. With a non-inferiority margin of
9% and an expected loss to follow-up of 10%, 424 women will be needed to prove non-inferiority with a confidence
interval of 95%.
Discussion: This study will evaluate the effectiveness and costs of SSH versus MM in women with primary POP. The
evidence will show whether the existing PPV is detrimental and a de-implementation process regarding one of the
operations is needed.
Trial registration: Dutch Trial Register (NTR 6978, http://www.trialregister.nl). Date of registration: 29 January 2018.
Prospectively registered.
Keywords: Sacrospinous hysteropexy, Modified Manchester operation, Uterine descent, Pelvic organ prolapse, POP-Q,
Reconstructive surgery, Randomized clinical trial, Cost-utility
Background
Pelvic organ prolapse (POP) is a frequently diagnosed
health problem in women which negatively affects the
quality of life. 40% of vaginally parous women have at least
stage 2 POP [1, 2]. In the Netherlands, 20% of all women
will undergo POP surgery during life time [3, 4]. According
to the current guidelines, the first choice surgical treatment
is a vaginal POP operation [5]. When undergoing surgery
these women have a 5–30% risk on re-operation due to
recurrence [2, 6]. According to a nationwide Dutch regis-
tration (Kiwa Carity), 15,000 vaginally POP procedures are
performed each year in the Netherlands [7]. Currently,
three types of vaginal operations for uterine descent are
performed the most; the vaginal hysterectomy (VH), the
modified Manchester operation (MM) and the sacrospi-
nous hysteropexy (SSH), all combined with colporrhaphy
when indicated. SSH and MM are uterus preserving
techniques in which the uterus is attached to different
pelvic ligaments. The number of uterus sparing operations
(SSH and MM) has increased more than fivefold between
1997 and 2009 in the Netherlands, at the expense of VH
[8]. Still the three surgical treatments co-exist without solid
evidence-based literature on comparison, which leads to
practice pattern variation (PPV) between hospitals and
gynaecologists. PPV is defined as a difference in care that
cannot be explained by the underlying medical condition
[9]. For example, in the Netherlands choice of treatment is
more or less equally divided between the three procedures
for women with stage two uterine descent (varying from 25
to 34%) [7, 8]. This indicates a situation of maximal prac-
tice pattern variation. The choice of treatment is dictated
by the physician’s preference or skills and is (probably) not
evidence based. Theoretically, PPV can lead to increased
health costs. Additionally, the lack of evidence makes it
more difficult to come to a process of shared decision mak-
ing between doctor and patient and individually tailored
management in this field.
First steps have been made in filling the knowledge gap;
the comparison VH versus SSH has been made in several
studies [10–12], and was well established by the SAVE-U
randomized multicentre trial [13]. The latter showed equal
effectiveness, but shorter operation times in SSH. In case
of patient’s preference for uterus preservation [14], the
SAVE-U publications have provided arguments to choose
for uterus sparing surgery. Recently published systematic
reviews by Kapoor et al. and Meriwether et al. confirmed
these findings and additionally less blood loss was
reported favouring uterus sparing surgery [15, 16]. Unlike
these results, the systematic review by de Oliveira et al.
showed a lower reoperation rate after VH. However, this
review focused on more advanced uterine prolapse (at
least stage II, POP-Q point C > 1 cm) [17].
The Manchester operation was first described in 1888
and has since gained ground in urogynaecology. Originally,
the operation was a combination of a cervix amputation
with anterior colporrhaphy [18]. Later, the cardinal liga-
ments were plicated and attached to the cervical stump
and today the modern version of the operation is applied
in which the sacro-uterine ligaments are plicated as well.
Despite the scarcity in studies comparing the MM to other
operating techniques, a recent historical cohort study by
Tolstrup et al. showed superiority of MM compared to VH
[19]. In addition, a recent prospective cohort study showed
that the MM provides adequate mid-compartment support
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and gives excellent subjective results after one-year
follow up [20].
It is thought that in case of an elongated cervix, MM
may be more suitable than SSH. On the other hand, MM
may lead to cervical stenosis (menstrual obstruction, poor
access for diagnostics) which was reported up to 11% [21].
At the same time, previous studies have shown that SSH
can be performed with a reduced operating time of
approximately 19min compared to MM (SSH 59 ± 13
min vs. MM 78 ± 28min) [22, 23].
Uterine descent stage 3 is generally not treated with
MM (but with VH or SSH), which was also seen in a
cohort study on MM [24]. Although MM is performed
approximately 3000 times a year in the Netherlands, still
little is known about the effectiveness compared to SSH.
To our knowledge, most publications on MM and SSH
for treatment of POP are based on observational studies.
Only one recently performed randomized clinical trial
compared the techniques, but contradictive to our design,
women with uterine prolapse all underwent hysterectomy
[25]. A randomized clinical trial comparing the SSH and
MM with preservation of the uterus has not yet been per-
formed. The PPV, women’s preference and upcoming
trend towards uterus preserving surgery makes it inevit-
able to further fill the knowledge gap. This study will
provide answer to the question: Is SSH non-inferior to
MM in women with signs and symptoms of POP?
Methods/design
Study objectives and hypothesis
The objective of this study is to compare the effectiveness
of SSH and MM in the treatment of uterine prolapse with
POP-Q point D ≤minus 1 cm. Comparison will be made
concerning anatomy, symptoms, re-interventions, POP-re-
currence, complications, hospital parameters, pelvic floor
dysfunction, quality of life and costs with a follow-up of
two years. Based on the current literature, it is hypothe-
sized that both techniques are comparable regarding effect-
iveness, that is to say the composite outcome of recurrent
anatomical POP with complaints or reoperation or pessary
therapy.
Study design
The SAM study is a multicentre, prospective, random-
ized, open-label clinical trial aimed at assessing the
non-inferiority of the effectiveness of SSH compared to
MM. This protocol was developed according to the
Standardized Protocol Interventions: Recommendations
for Interventional Trials (SPIRIT) 2013 statement [26].
Study population, recruitment and consent
Women aged 18 or older who are eligible for their first
surgical treatment for symptomatic pelvic organ pro-
lapse in any stage and with uterine descent and POP-Q
point D at ≤ minus 1 cm will be eligible for the study.
We do not consider MM to be the appropriate treat-
ment for women with POP-Q point D >minus 1 cm,
since we believe that beyond that point the sacro-uterine
ligaments will not provide substantial support. In that
case, the patient would benefit more from an SSH.
Patients with concomitant anterior or posterior wall
prolapse will be included.
Women who underwent previous prolapse or other
pelvic floor surgery, need concomitant mid-urethral sling
surgery, have a wish or need for uterus removal, have a
contraindication for uterus preservation (i.e. abnormal
endometrial bleeding, endometrial or cervical malig-
nancy), have a future wish for childbearing, have inad-
equate skills in the Dutch language or are not capable of
filling in questionnaires will be excluded from the study.
In case indicated, a pap-smear and/or pipelle endometrial
biopsy must be normal before inclusion.
Participating centres will be 27 Dutch university, teach-
ing and non-teaching hospitals (a list of participating cen-
tres is available at: http://zorgevaluatienederland.nl/sam).
The SAM study is affiliated with the Dutch Consortium
for Healthcare Evaluation and Research in Obstetrics and
Gynaecology, which gives national attention and therefore
ensures the right amount of participating hospitals to
achieve adequate patient enrolment. Gynaecologists and
trainees of all participating hospitals will perform the eligi-
bility assessment. Eligible patients will be counselled about
the study, the two operating techniques and follow-up. All
patients will be provided written patient information which
contains information about the aim of the study, follow-up,
advantages and disadvantages. Patients will be given a week
to make their decision on participation in the study.
Women who agree to participate will be asked to sign writ-
ten informed consent. The informed consent form will be
obtained and signed by the investigator before randomisa-
tion. The rules of Good Clinical Practice will be applied.
All eligible patients who are counselled will be registered
during inclusion period. From patients who do not want to
participate, only reasons for refusal will be registered. All
serious adverse events will be reported to the Medical
Ethics Committee. Patient enrolment en recruitment is
currently ongoing. 3 July 2018 the first patient enrolled the
study. Enrolment is expected to conclude August 2020.
Intervention
SSH: after opening the posterior vaginal wall, the para-
rectal space is explored at the right side and the sacros-
pinous ligament is identified. The posterior side of the
cervix is attached to the sacrospinous ligament with two
non-absorbable size 1 or 0 sutures at least 2 cm medial
of the ischial spine. Either this procedure is performed
open or using the Capio suturing device.
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MM: the procedure consists of extraperitoneal plication
of the uterosacral ligaments (and cardinal ligaments where
possible) with use of three or four absorbable size 1 sutures
and amputation of the cervix. The most cranial suture is
fixated through the posterior fornix of the vagina.
In view of substantial variation in operative skills and ex-
perience there will be attention to avoid the measurement
of learning curve effects in the study. Only centres where
both techniques are performed before the start of the study
or where mentoring/supervision is organised can partici-
pate in the study. All participating gynaecologists must
have performed at least one hundred POP procedures,
twenty procedures of each technique of which ten
performed in the last three years before the beginning of
the study. Before the study started, all participating gynae-
cologists were invited to a master class to discuss all steps
of both procedures, to minimize practice variation. Agree-
ment was reached by all participating gynaecologists. One
uniform operation report for each procedure was written
after these master classes and is used during the study.
Only a few steps of the operation will be left to the prefer-
ence of the gynaecologist, namely: application and type of
hydrodissection, manner of cervical amputation and use of
scalpel or scissors for opening the vaginal wall. All these
steps will be registered. Allocated interventions will only be
modified or discontinued in case the operating gynaecolo-
gist believes this is necessary during operation. This will be
registered.
Anaesthesia will be either general or spinal, depending
on the anaesthesiologist and patient preferences. Antibi-
otics will be given peri-operatively according to the hos-
pital protocol. Bladder catheterisation will be done before
operating one-off or with an indwelling catheter. After op-
eration an indwelling catheter must remain in the bladder
until the next morning. Urinary retention after removal
will be reported. For both procedures anterior and/or pos-
terior colporrhaphy will be performed as indicated.
Outcome measures
The primary outcome will be success after two years
follow-up. Success is defined as the absence of POP beyond
the hymen in any compartment (POP-Q, gynaecological
examination), the absence of bulge symptoms (absence of
bulge symptoms is defined as a negative response to the
question, “Do you see or feel a bulge in the vaginal area”
(UDI domain genital prolapse score: 0)), and absence of
reoperation or pessary therapy for POP [27].
Secondary outcomes of the study will be clinical parame-
ters (surgery time, hospitalisation time), surgery related
morbidity/complications (including menstrual problems,
hematometra, any problems with uterine access such as
diagnostic cervical or endometrial sampling or IUD inser-
tion), pain perception, further treatments for POP or urin-
ary incontinence, anatomy in all compartments using
POPQ [28], general quality of life, disease specific quality of
life regarding symptoms and impact of symptoms, sexual
function, and costs.
Randomization
After giving informed consent, patients will be randomized
in a 1:1 ratio to either MM or SSH, with use of dynamic
block randomisation with blocks of 2, 4 or 6. Randomisa-
tion will be done by gynaecologists or research nurses using
the online software Castor (version 2018.3.11, Castor Elec-
tronic Data Capture, Amsterdam, The Netherlands). Due
to the nature of the investigational treatments, blinding is
not possible. Participating gynaecologists and investigators
will not be able to access the randomization sequence. All
analyses will be performed in a blinded fashion.
Sample size calculation
The sample size calculation was based on the expected
comparability between the two techniques regarding the
success composite of recurrent signs and symptoms of
POP after two-years follow-up. We expect a success rate
of 89% for both SSH [13] and MM, two years after the
intervention. The actual treatment group proportion
(SSH) was set at 89% with a non-inferiority margin of
9%, assuming SSH to be below 80% under the null
hypothesis of inferiority. The 9% non-inferiority margin
was motivated by the margins used in two other large
national studies SAVE-U (7%) [13] and PEOPLE study
(10%) [29]. Based on a power of 80% and the significance
level of the test (α) targeted at 0.025, sample sizes of 193
per group need to be included in the study. With an
expected loss to follow-up of 10% [27], a total of 424
women are needed. The sample size calculation was
performed with PASS (version 15.0.7, NCSS statistical
software, Kaysville, USA).
Data collection
All women will undergo gynaecological examination
including POP-Q which must be done in 45 degrees
supine position. All measurements performed during
pre-operative and follow-up outpatients visits, as well as
the operation report, will be systematically recorded in
an electronic Case Report Form in Castor. All data will
be kept anonymous where possible. All participants will
be assigned an identification code based on number of
the hospital and number of inclusion. A list linking the
code to the subject will be kept safe by the local
investigators. Personal data will be stored for a max-
imum of 15 years in participating centres.After
randomization patients will be sent an e-mail with a link
to the pre-operative questionnaires in Castor. If the sub-
ject prefers paper questionnaires, written informed con-
sent is needed to get insight in the postal address of the
subject. Both groups will fill in the same questionnaires.
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The pre-operative questionnaire consists of questions on
baseline characteristics, and standardized, validated ques-
tionnaires about quality of life (EQ5D-5 L: EuroQol-5D-5
L) [30], disease specific quality of life regarding symptoms
(Pelvic Floor Disability Index-20) and the impact of those
symptoms (Pelvic Floor Impact Questionnaire-7) [31], sex-
ual function (Pelvic organ prolapse Incontinence Sexual
Questionnaire-IR) [32], and the validated cost utility ques-
tionnaires of the institute for Medical Technology Assess-
ment (iMTA) (PCQ: Productivity Cost questionnaire and
MCQ: Medical Consumption Questionnaire) [33]. After
surgery, the patients will visit the hospital at 6 weeks, 12
months and 24months (see Table 1). During the follow-up
specific history taking and gynaecological examination in-
cluding POP-Q will be done. The POP-Q at 12 and 24
months will be performed by another researcher than the
operating gynaecologist. Reimbursement of travel expenses
is available to minimize no shows. At 6months, 12months
and 24months patients will receive abovementioned ques-
tionnaires and an additional disease specific questionnaire
(Patient Global Impression of Improvement). At 12 weeks
and 9months patients receive the PCQ, MCQ and
EQ5D-5 L; these extra moments are incorporated to
prevent recall bias. Reminders will be sent after two weeks
in case of non-completion of questionnaires. The duration
of the follow-up period is set at 2 years because the major-
ity of recurrences after POP surgery will occur in these first
two years [34, 35]. Women will be asked for permission to
ask them to participate in a longer follow-up study in case
this seems valuable after the two year analysis.
Statistical analysis
Data analysis
Regarding the primary outcome, the null hypothesis en-
tails that the success rate of SSH is inferior by a margin
of 9% compared to MM. If the lower limit of the 95%
confidence interval does not exceed the margin of − 9%,
the null hypothesis is rejected, and we will consider SSH
to be non-inferior to MM. The statistical analysis will be
performed both by the intention to treat (ITT) and per
protocol (PP) principle. This means that non-inferiority
has to be demonstrated in both the ITT and PP analysis
to declare non-inferiority of SSH compared to MM. The
treatment effect will be expressed as relative risk with a
95% confidence interval.
For other (secondary) outcomes, summaries of continu-
ous data will be presented as mean ± standard deviation or
median and (interquartile) range depending on their distri-
bution. Categorical data will be presented as frequencies.
When appropriate, differences between groups will be ana-
lysed using the Student’s t test or Mann-Whitney test for
continuous data. Comparisons with categorical data will be
analyzed using the Chi-square test of the Fisher’s exact test.
Other study parameters
Subgroup analyses are planned to investigate the effects of
the POP surgery with MM versus SSH in the following
pre-specified subgroups: age, menopausal status, sexual
activity, POP-Q stage, cervical elongation, concomitant
vaginal repair and symptoms.
A prognostic marker analysis will be performed to assess
which baseline characteristics of the women have prog-
nostic value and/or can be used as treatment selection
markers. Missing covariates will be imputed as appropri-
ate (with solid logical strategy). We will use multiple
imputation based on other baseline variables that are asso-
ciated with higher or lower values of the variable that is
imputed. We will do sensitivity analyses to evaluate the
difference between imputed and non-imputed variables.
All analyses will be performed with IBM SPSS Statistics
(version 25, Armonk, New York, United States).
Economic evaluation
The economic evaluation will be performed along-side the
clinical trial, which will compare the cost-effectiveness up
to 12months after surgery from a societal perspective.
The design of the economic evaluation follows the princi-
ples of a cost-utility analysis and adheres to the Dutch
guideline for performing economic evaluations in health
care [36]. Costs and effects will be measured on a per
patient basis. The cost analysis exists of two main parts.
On patient level, the costs made within healthcare, costs
made by patients/family and costs in other sectors than
healthcare will be included. Second, per item of health
care consumption standard cost-prices will be determined
using the guideline for performing economic evaluations
Table 1 Schematic overview of follow-up
Measurement Follow-up moment
Pre-op 6 wks 12 wks 6 months 9 months 12months 24 months
Outpatient visit including POP-Q x x x
Baseline characteristics x
EQ5D-5 L x x x x x x
PDFI-20, PGI-I, PFIQ-7, PISQ-IR xa x x x
PCQ and MCQ x x x x x
awithout PGI-I
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[36]. If standardized prices are not available, full cost
prices will be determined via activity-based costing. Prod-
uctivity losses for patients will be assessed using the iMTA
PCQ. The friction-cost method will be applied and in
addition, travel time to the hospital and related costs will
be considered. It is anticipated that SSH is as effective but
significantly cheaper (less operating time) than MM in this
target population. If the results confirm this, a cost-
minimization analysis will be the method of analysis. Cost
will be analysed using a generalized linear model approach
with a gamma distribution using a log link to account for
possible skewness of the cost data. The effect analysis mea-
sures, on previous mentioned follow-up moments, the clin-
ical trial Health Related Quality of Life using de EQ5D-5 L.
Additionally, a budget impact analysis will be performed
for consequences of implementation of SSH substituting
for MM in the Dutch health care system in the short-to-
medium term from the budget holders perspective [37].
The economic analyses will be presented as a separate
study.
Implementability
The current usual care can best be described as: large
PPV regarding vaginal POP surgery in women who
undergo their first POP operation. The study results
should change this usual care in the following way:
implementation of the most cost-effective technique of
uterus sparing vaginal POP operation. To increase the
generalizability and the implementability of the results,
the study will be performed according to high standards
in those centres with research facilities of the NVOG
Consortium 2.0. Representatives of most target groups
are thus involved as including centre or as members of
the project group. It is known that implementation is ex-
tremely facilitated by involvement in evidence collection
[38]. Moreover, these results will be translated into
specific and clear recommendations for national clinical
guidelines, which will be incorporated in the guideline
facilitated by the Dutch Society for Obstetricians and
Gynaecologists (NVOG). In addition, the following activ-
ities will be performed to transfer our knowledge: study
results will be published in an international journal,
study results will be disseminated among participants
and opinion leaders, results will be incorporated in edu-
cation programs and patient organizations will distribute
the results to their respective platforms and patient
information leaflets will be updated.
To optimize implementation of our study results we will
focus on potential barriers and facilitators from the start of
the study [38]. For that purpose, we will perform qualitative
research among the final target users (patients and clinical
professionals (e.g. participants and non-participants of this
proposed study).
Discussion
This is a protocol for a randomized clinical trial compar-
ing SSH with MM. To our knowledge this will be the
first large randomized study with mid-term follow-up
that will compare these two uterus sparing operative
techniques. The study will provide knowledge that can
lead the way in the best individual treatment in women
with POP, can be used to supplement the current guide-
lines and may show the need for de-implementation of
one of the procedures. The study will reveal whether the
existing PPV is unwanted or not significant in terms of
effectiveness and costs. In case non-inferiority is found,
the secondary outcomes might determine the preferred
uterus preserving technique.
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